全球動物模型市場規模、佔有率、成長分析、按類型、按應用分類 - 2023-2030 年產業預測

Global Animal Model Market Size, Share, Growth Analysis, By Type(Pigs, Cats), By Application(Research and Development, Production) - Industry Forecast 2023-2030

出版日期: 2024年02月04日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球動物模型市場規模為22.6億美元，從2023年的24.4億美元成長到2031年的44.4億美元，預測期內（2024-2031年）複合年成長率為7.8%。成長至 10,000,000 美元。

動物模型市場的目的是為研究人員提供高度可靠的模型，忠實地再現人類生理和病理。市場成長主要是由癌症、心血管疾病和神經系統疾病等慢性和複雜疾病的盛行率上升所推動的。特別是基因改造動物模型（例如基因轉殖小鼠）的進步提供了非凡的機會，使研究人員能夠深入研究特定基因及其在疾病進展中的作用。此外，對個人化醫療和客製化治療的需求不斷成長，為開發源自患者的動物模型和精準醫療方法提供了機會。全球動物模型市場對於科學知識的進步和藥物開發具有至關重要的意義。儘管存在倫理問題和替代技術出現等挑戰，該市場仍繼續為了解疾病和開發新治療方法提供重要工具。動物模型的持續技術創新和對個人化醫療日益成長的需求預示著該領域的進一步發展和進步。

使用自上而下和自下而上的方法來估計和檢驗動物模型的全球市場規模，並估計其他各個相關子市場的規模。用於估計市場規模的調查方法包括以下詳細資訊：用於確定市場主要企業的二次研究，用於確定每個地區的市場佔有率的主要和二次研究。整個過程包括研究主要企業的年度和財務報告以及廣泛的採訪，以獲得執行長、副總裁、董事和行銷負責人等行業領導者的重要見解。所有股份比率和細分均使用二手資訊確定並使用主要資訊檢驗。本研究涵蓋的所有可能影響市場的參數都經過了考慮、詳細研究、初步研究檢驗和分析，以獲得最終的定量和定性資料。

全球動物模型市場細分分析

全球動物模型市場根據類型、應用和地區進行細分。按類型分類，市場分為豬、貓和小鼠。依用途分為研發、生產、品管。按地區分類，市場分為北美、歐洲、亞太地區、中東和非洲以及拉丁美洲。

全球動物模型市場的促進因素

隨著基因組學和精準醫學的不斷發展，對能夠準確再現個別患者特徵和治療反應的動物模型的需求不斷成長。研究人員和製藥公司越來越依賴動物模型來研究特定的遺傳變異並開發標靶治療。特別是，患者來源的異種移植（PDX）模型的採用將在 2022 年獲得勢頭，將患者腫瘤樣本移植到動物宿主中進行藥物測試。這些模型能夠評估針對個別患者的治療效果，有助於個人化醫療中對動物模型不斷成長的需求。

基因編輯技術，尤其是CRISPR-Cas9的快速發展，已成為2022年動物模型市場的另一個關鍵驅動力。這些技術有助於精確操作動物模型中的基因，並能夠創建與人類疾病非常相似的基因轉殖模型。透過將特定的基因突變和修飾引入動物模型，研究和開發可以探索疾病的潛在機制並開發創新的治療方法。 2022年基因編輯技術的廣泛採用對於增加動物模型的使用和促進該領域的創新發揮了關鍵作用。

全球動物模型市場的限制因素

儘管動物模型領域取得了重大進展，但倫理問題和動物福利考量在 2022 年仍然是重要的限制因素。在研究活動中使用動物引發了倫理問題，並引發了有關動物人道待遇的爭論。對動物福利法規的審查和公眾的關注導致對動物模型的使用進行更嚴格的審查，特別是在動物福利法規嚴格的國家。這種倫理問題和法律規範對動物模型市場的擴張提出了挑戰，並鼓勵探索替代技術和模型。

2022 年市場中觀察到的另一個阻礙因素是與維護動物設施、購買和飼養動物以及使用動物模型進行實驗相關的高成本和複雜性。動物模型需要專用設施、專門照顧和資源，導致維修成本高。此外，與使用動物模型相關的複雜性，例如需要經驗豐富的人員、遵守法規要求以及物流挑戰，都會增加整體成本。這些成本和複雜性因素可能會限制動物模型的取得和使用，特別是對於預算有限的小型研究機構。

全球動物模型市場趨勢

2022 年動物模型市場的一個顯著趨勢是越來越重視人源化和轉換模型。研究人員正積極致力於創建更能反映人類生理學、疾病進展和藥物反應的動物模型。這一趨勢包括將人類細胞、組織和基因修飾涵蓋動物模型中，以增加其與人類疾病的相關性。例如，開發具有人類免疫系統的人源化小鼠將使免疫相關疾病的更精確研究和免疫療法測試成為可能。 2022 年人源化和轉化模型的轉變凸顯了該產業對提高動物模型在人類疾病研究中的可預測性和適用性的承諾。

執行摘要
調查方法
母市場分析
主要市場考察
- 技術分析
- 價格分析
- 供應鏈分析
- 價值鏈分析
- 市場生態系統
- 智慧財產權分析
- 貿易分析
- Start-Ups分析
- 原料分析
- 創新矩陣
- 研發線產品分析
- 總體經濟指標
- 主要投資分析
- 關鍵成功因素
- 競爭程度
市場動態及展望
- 市場動態
  - 促進因素
  - 機會
  - 抑制因素
  - 任務
- 監管形勢
- 波特的分析
- 對未來中斷的特殊考慮
全球動物模型市場：按類型
- 市場概況
- 豬
- 貓
- 小鼠或大鼠
全球動物模型市場：依應用分類
- 市場概況
- 研究與開發
- 生產
- 品管
全球動物模型市場規模：按地區分類
- 市場概況
- 北美洲
  - 美國
  - 加拿大
- 歐洲
  - 德國
  - 西班牙
  - 法國
  - 英國
  - 其他歐洲國家地區
- 亞太地區
  - 中國
  - 印度
  - 日本
  - 韓國
  - 其他亞太地區
- 拉丁美洲
  - 巴西
  - 其他拉丁美洲地區
- 中東和非洲 (MEA)
  - 海灣合作理事會國家
  - 南非
  - 其他中東/非洲地區
競爭形勢
- 前5名企業對比
- 主要企業市場定位（2021年）
- 主要市場參與者所採取的策略
- 關鍵成功策略
- 近期市集活動
- 主要企業市場佔有率（2021年）
主要企業簡介
- Charles River Laboratories International Inc.（US）
- Envigo（US）
- The Jackson Laboratory（US）
- Taconic Biosciences Inc.（US）
- genOway SA（France）
- Horizon Discovery Group plc（UK）
- TransGenic Inc.（Japan）
- Crown Bioscience Inc.（US）
- Janvier Labs（France）
- Laboratory Corporation of America Holdings（US）
- Harbour Antibodies BV（Netherlands）
- Eurofins Scientific（Luxembourg）
- Biocytogen LLC（US）
- Transnetyx Inc.（US）
- Ingenious Targeting Laboratory（US）
- Charles River Japan（Japan）
- Cyagen Biosciences Inc.（US）
- Ozgene Pty Ltd（Australia）
- Hera Biolabs Inc.（US）
- Pharmaron Beijing Co., Ltd.（China）

簡介目錄

Product Code: SQMIG35A2418

Global Animal Model Market size was valued at USD 2.26 Billion in 2022 and is poised to grow from USD 2.44 Billion in 2023 to USD 4.44 Billion by 2031, at a CAGR of 7.8% during the forecast period (2024-2031).

The animal model market serves the purpose of furnishing researchers with dependable models that closely emulate human physiology and pathophysiology. The market's growth is primarily driven by the escalating prevalence of chronic and intricate diseases like cancer, cardiovascular disorders, and neurological conditions. It presents notable opportunities, particularly with the advancement of genetically modified animal models like transgenic mice, enabling researchers to delve into specific genes and their roles in disease progression. Furthermore, the increasing demand for personalized medicine and tailored therapies creates avenues for developing patient-derived animal models and precision medicine approaches. The global animal model market holds pivotal significance in advancing scientific knowledge and drug development. Despite encountering challenges such as ethical concerns and the emergence of alternative technologies, the market persists in offering indispensable tools for comprehending diseases and devising new treatments. The continual innovation in animal models and the surging demand for personalized medicine augur well for further growth and progress in this domain.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Animal Model Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Animal Model Market Segmental Analysis

The global animal model market is segmented on the basis of type, application, and region. Based on type, the market is segmented into pigs, cats, and mice. By Application, the market is segmented into research and development, production, and quality control. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Animal Model Market

As genomics and precision medicine continue to advance, there is a growing demand for animal models that can accurately replicate individual patient characteristics and responses to treatments. Researchers and pharmaceutical companies are increasingly relying on animal models to investigate specific genetic variations and develop targeted therapies. Notably, the adoption of patient-derived xenograft (PDX) models gained momentum in 2022, where animal hosts are implanted with patient tumour samples for drug testing. These models enable the assessment of treatment efficacy tailored to individual patients, contributing to the heightened demand for animal models in personalized medicine.

The rapid progress of gene editing technologies, particularly CRISPR-Cas9, emerged as another significant driver in the 2022 animal model market. These technologies facilitate precise manipulation of genes in animal models, allowing the creation of genetically modified models that closely resemble human diseases. Researchers can introduce specific genetic mutations or modifications in animal models to explore the underlying mechanisms of diseases and develop innovative therapeutics. The widespread adoption of gene editing technologies in 2022 played a pivotal role in increasing the utilization of animal models and fostering innovation in the field.

Restraints in the Global Animal Model Market

Despite notable advancements in the field of animal models, ethical concerns and considerations for animal welfare remained significant constraints in 2022. The use of animals in research activities raises ethical questions and triggers debates regarding the humane treatment of animals. The scrutiny of animal welfare regulations and public attention has led to increased oversight of the use of animal models, especially in countries with stringent regulations pertaining to animal welfare. These ethical concerns and regulatory frameworks pose challenges to the expansion of the animal model market and incentivize the exploration of alternative technologies and models.

Another impediment observed in the market in 2022 was the high costs and complexities associated with maintaining animal facilities, procuring and breeding animals, and conducting experiments using animal models. Animal models demand dedicated facilities, specialized care, and resources, contributing to their substantial maintenance costs. Furthermore, the intricacies associated with working with animal models, such as the need for experienced personnel, adherence to regulatory requirements, and logistical challenges, amplify the overall expenses. These cost and complexity factors can restrict the accessibility and utilization of animal models, particularly for smaller research organizations operating with limited budgets.

Market Trends of the Global Animal Model Market

A notable trend observed in the 2022 animal model market was the growing emphasis on humanized and translational models. Researchers are actively working to create animal models that closely mirror human physiology, disease progression, and responses to drugs. This trend involves the integration of human cells, tissues, or genetic modifications into animal models to enhance their relevance to human diseases. For instance, the development of humanized mice with a human immune system allows for more accurate studies of immune-related diseases and testing of immunotherapies. The shift towards humanized and translational models in 2022 underscores the industry's commitment to enhancing the predictability and applicability of animal models in human disease research.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
- Regulatory Landscape
- Porters Analysis
  - Competitive rivalry
  - Threat of Substitute Products
  - Bargaining Power of Buyers
  - Threat of New Entrants
  - Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
  - Political Impact
  - Economic Impact
  - Social Impact
  - Technical Impact
  - Environmental Impact
  - Legal Impact
Global Animal Model Market by Type
- Market Overview
- Pigs
- Cats
- and Mice
Global Animal Model Market by Application
- Market Overview
- Research and Development
- Production
- and Quality Control
Global Animal Model Market Size by Region
- Market Overview
- North America
  - USA
  - Canada
- Europe
  - Germany
  - Spain
  - France
  - UK
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - South Korea
  - Rest of Asia-Pacific
- Latin America
  - Brazil
  - Rest of Latin America
- Middle East & Africa (MEA)
  - GCC Countries
  - South Africa
  - Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
  - By Development
  - By Company
  - By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Charles River Laboratories International Inc. (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Envigo (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- The Jackson Laboratory (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Taconic Biosciences Inc. (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- genOway SA (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Horizon Discovery Group plc (UK)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- TransGenic Inc. (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Crown Bioscience Inc. (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Janvier Labs (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Laboratory Corporation of America Holdings (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Harbour Antibodies BV (Netherlands)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Eurofins Scientific (Luxembourg)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Biocytogen LLC (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Transnetyx Inc. (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Ingenious Targeting Laboratory (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Charles River Japan (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Cyagen Biosciences Inc. (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Ozgene Pty Ltd (Australia)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Hera Biolabs Inc. (US)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Pharmaron Beijing Co., Ltd. (China)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments